Quantcast

Latest Neuroprotection Stories

2010-01-19 14:00:00

NEW YORK, Jan. 19 /PRNewswire-USNewswire/ -- As part of its mission to speed development of transformative treatments for Parkinson's disease, The Michael J. Fox Foundation for Parkinson's Research announced a total of $2.1 million in awards to six biotech and pharmaceutical companies under its industry-exclusive Therapeutics Development Initiative (TDI). The funding will drive pre-clinical projects pushing forward investigations of promising neuroprotective therapeutic targets for...

2009-12-11 13:04:20

Following up on their previous work showing the rescue of dopamine neurons by chemicals that interact with the retinoid X receptor (RXR), researchers have now investigated the potential of these chemicals, known as RXR ligands, for the treatment of Parkinson's disease. Writing in the open access journal BMC Neuroscience the scientists describe the use of two cellular models of Parkinsonian damage to explore the neuroprotective function of the two RXR ligands LG268 and XCT. Susanna Kjellander...

2009-12-10 15:27:00

NEW YORK, Dec. 10 /PRNewswire-USNewswire/ -- As part of its mission to accelerate promising therapeutic targets through the development pipeline toward clinical trials and, ultimately, patient care, The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced that it has awarded a total of $1.3 million to nine research teams working to develop potentially disease-modifying therapies for Parkinson's disease. Research into disease-modifying therapies is a key priority for MJFF,...

2009-11-30 21:49:23

New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease "“ findings that could point the way to a new type of therapy. The results surprised researchers, since lead is also a known risk factor for ALS. This paradox is still not fully understood, and at this point would not form the basis for a therapy, as lead is toxic for the nervous system. But scientists...

2009-11-17 09:00:00

JACKSONVILLE, Fla., Nov. 17 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Series "A" Preferred stock offering that has raised $510,000 for its ongoing drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window...

2009-11-04 09:00:00

CLARKSVILLE, Md., Nov. 4 /PRNewswire/ -- Neuronascent, Inc., a privately-held biotechnology company developing novel, neurogenic small-molecule drugs for the treatment of depression, Alzheimer's disease, Parkinson's and other neurodegenerative diseases, announces it has entered into a discovery agreement with ChemRar Pharma, a Russian biotechnology start-up company focusing on small-molecule modulators for developmental pathways and stem cells to treat cancer. Under the terms of the...

2009-10-28 22:05:28

Scientists at the University of California, San Diego School of Medicine report that regeneration of central nervous system axons can be achieved in rats even when treatment delayed is more than a year after the original spinal cord injury. "The good news is that when axons have been cut due to spinal cord injury, they can be coaxed to regenerate if a combination of treatments is applied," said lead author Mark Tuszynski, MD, PhD, professor of neurosciences and director of the Center for...

2009-10-22 08:06:59

The inflammatory response following a spinal cord injury appears to be set up to cause extra tissue damage instead of promoting healing, new research suggests. Scientists analyzing this inflammatory response in mice discovered that the types of cells recruited to the site of the injury are dominated within a week by those that promote inflammation. When chronic, inflammation can prevent healing, and these inflammatory cells are believed to remain at the injury site indefinitely. Meanwhile,...

2009-10-19 17:53:22

Glutamate is to the brain like coffee is to our bodies. A cup of Joe in the morning can wake us, but overloading on caffeine causes the stimulant to work against us. Glutamate is the major excitatory neurotransmitter in a mammal's central nervous system. It is an important component for neuroplasticity, the synaptic communication between neurons. It's also key to learning and memory. But in high concentrations, glutamate becomes toxic-- over-exciting the neurons. Glutamate-induced...

2009-10-06 10:25:54

The antibiotic minocycline may revolutionize the treatment of strokes. A new study, published in the open access journal BMC Neuroscience, describes the safety and therapeutic efficacy of the drug in animal models. Dr. Cesar V. Borlongan from the University of South Florida, USA worked with a team of researchers to test the treatment in laboratory experiments. He said, "To date, the thrombolytic agent tPA is the only effective drug for acute ischemic stroke; however, only about 2% of ischemic...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related